



Age/Gender : 39 Y 10 M 22 D/F UHID/MR No : SCHI.0000019256

Visit ID : SCHIOPV28013

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : gtgrd Collected : 23/Mar/2024 10:36AM

Received : 23/Mar/2024 11:28AM Reported : 23/Mar/2024 03:26PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

PERIPHERAL SMEAR, WHOLE BLOOD EDTA

Dr. SHWETA GUPTA
MBBS,MD (Pathology)
Consultant Pathology
SIN No:BED240080214

Page 1 of 16







: Mrs.POOJA KAPOOR

Age/Gender

: 39 Y 10 M 22 D/F

UHID/MR No

: SCHI.0000019256

Visit ID Ref Doctor : SCHIOPV28013

Emp/Auth/TPA ID

: Dr.SELF : gtgrd Collected

Status

: 23/Mar/2024 10:36AM

Received

: 23/Mar/2024 11:28AM

Reported

: 23/Mar/2024 03:26PM : Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
HEMOGRAM , WHOLE BLOOD EDTA				
HAEMOGLOBIN	13.3	g/dL	12-15	CYANIDE FREE COLOUROMETER
PCV	41.40	%	40-50	PULSE HEIGHT AVERAGE
RBC COUNT	5.1	Million/cu.mm	3.8-4.8	Electrical Impedence
MCV	81.2	fL	83-101	Calculated
MCH	26.1	pg	27-32	Calculated
MCHC	32.1	g/dL	31.5-34.5	Calculated
R.D.W	15	%	11.6-14	Calculated
TOTAL LEUCOCYTE COUNT (TLC)	5,930	cells/cu.mm	4000-10000	Electrical Impedance
DIFFERENTIAL LEUCOCYTIC COUNT	(DLC)	'		<u>'</u>
NEUTROPHILS	55.2	%	40-80	Electrical Impedance
LYMPHOCYTES	32.3	%	20-40	Electrical Impedance
EOSINOPHILS	3.2	%	1-6	Electrical Impedance
MONOCYTES	8.5	%	2-10	Electrical Impedance
BASOPHILS	0.8	%	<1-2	Electrical Impedance
ABSOLUTE LEUCOCYTE COUNT		'		<u>'</u>
NEUTROPHILS	3273.36	Cells/cu.mm	2000-7000	Calculated
LYMPHOCYTES	1915.39	Cells/cu.mm	1000-3000	Calculated
EOSINOPHILS	189.76	Cells/cu.mm	20-500	Calculated
MONOCYTES	504.05	Cells/cu.mm	200-1000	Calculated
BASOPHILS	47.44	Cells/cu.mm	0-100	Calculated
Neutrophil lymphocyte ratio (NLR)	1.71		0.78- 3.53	Calculated
PLATELET COUNT	187000	cells/cu.mm	150000-410000	IMPEDENCE/MICROSCOPY
ERYTHROCYTE SEDIMENTATION RATE (ESR)	17	mm at the end of 1 hour	0-20	Modified Westergren
PERIPHERAL SMEAR				

RBCs ARE NORMOCYTIC NORMOCHROMIC.

TLC , DLC WITHIN NORMAL LIMIT. NO IMMATURE CELLS ARE SEEN. PLATELETS ARE ADEQUATE.

Page 2 of 16







Age/Gender : 39 Y 10 M 22 D/F

UHID/MR No : SCHI.0000019256

Visit ID : SCHIOPV28013

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : gtgrd Collected : 23/Mar/2024 10:36AM

Received : 23/Mar/2024 11:28AM Reported : 23/Mar/2024 03:26PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - TMT - PAN INDIA - FY2324

NO HEMOPARASITES SEEN

Page 3 of 16







Patient Name : Mrs.POOJA KAPOOR Age/Gender : 39 Y 10 M 22 D/F

UHID/MR No : SCHI.0000019256

Visit ID : SCHIOPV28013

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : gtgrd Collected : 23/Mar/2024 10:36AM Received : 23/Mar/2024 11:28AM

Reported : 23/Mar/2024 03:26PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method			
BLOOD GROUP ABO AND RH FACTOR, WHOLE BLOOD EDTA							
BLOOD GROUP TYPE	А			Forward & Reverse Grouping with Slide/Tube Aggluti			
Rh TYPE	POSITIVE			Forward & Reverse Grouping with Slide/Tube Agglutination			

Page 4 of 16









: Mrs.POOJA KAPOOR

Age/Gender

: 39 Y 10 M 22 D/F

UHID/MR No Visit ID : SCHI.0000019256

Ref Doctor

: SCHIOPV28013 : Dr.SELF

Emp/Auth/TPA ID : gtgrd

Collected

: 23/Mar/2024 03:44PM

Received

: 23/Mar/2024 04:11PM : 23/Mar/2024 08:59PM

Reported Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
GLUCOSE, FASTING, NAF PLASMA	95	mg/dL	70-100	GOD - POD

Comment:

As per American Diabetes Guidelines, 2023

P,	
Fasting Glucose Values in mg/dL	Interpretation
70-100 mg/dL	Normal
100-125 mg/dL	Prediabetes
≥126 mg/dL	Diabetes
<70 mg/dL	Hypoglycemia

Note:

- 1. The diagnosis of Diabetes requires a fasting plasma glucose of > or = 126 mg/dL and/or a random / 2 hr post glucose value of > or = 200 mg/dL on at least 2 occasions.
- 2. Very high glucose levels (>450 mg/dL in adults) may result in Diabetic Ketoacidosis & is considered critical.

Test Name	Result	Unit	Bio. Ref. Range	Method
GLUCOSE, POST PRANDIAL (PP), 2 HOURS, SODIUM FLUORIDE PLASMA (2 HR)	100	mg/dL	70-140	GOD - POD

Comment:

It is recommended that FBS and PPBS should be interpreted with respect to their Biological reference ranges and not with each other.

Conditions which may lead to lower postprandial glucose levels as compared to fasting glucose levels may be due to reactive hypoglycemia, dietary meal content, duration or timing of sampling after food digestion and absorption, medications such as insulin preparations, sulfonylureas, amylin analogues, or conditions such as overproduction of insulin.

Page 5 of 16







Age/Gender : 39 Y 10 M 22 D/F

UHID/MR No : SCHI.0000019256 Visit ID : SCHIOPV28013

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : gtgrd Collected : 23/Mar/2024 10:36AM Received : 23/Mar/2024 03:35PM

Reported : 23/Mar/2024 07:05PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method	
HBA1C (GLYCATED HEMOGLOBIN) , WHOLE BLOOD EDTA					
HBA1C, GLYCATED HEMOGLOBIN	5.6	%		HPLC	
ESTIMATED AVERAGE GLUCOSE (eAG)	114	mg/dL		Calculated	

Comment:

Reference Range as per American Diabetes Association (ADA) 2023 Guidelines:

REFERENCE GROUP	HBA1C %
NON DIABETIC	<5.7
PREDIABETES	5.7 – 6.4
DIABETES	≥ 6.5
DIABETICS	
EXCELLENT CONTROL	6 – 7
FAIR TO GOOD CONTROL	7 – 8
UNSATISFACTORY CONTROL	8 – 10
POOR CONTROL	>10

Note: Dietary preparation or fasting is not required.

- 1. HbA1C is recommended by American Diabetes Association for Diagnosing Diabetes and monitoring Glycemic Control by American Diabetes Association guidelines 2023.
- 2. Trends in HbA1C values is a better indicator of Glycemic control than a single test.
- 3. Low HbA1C in Non-Diabetic patients are associated with Anemia (Iron Deficiency/Hemolytic), Liver Disorders, Chronic Kidney Disease. Clinical Correlation is advised in interpretation of low Values.
- 4. Falsely low HbA1c (below 4%) may be observed in patients with clinical conditions that shorten erythrocyte life span or decrease mean erythrocyte age. HbA1c may not accurately reflect glycemic control when clinical conditions that affect erythrocyte survival are present.
- 5. In cases of Interference of Hemoglobin variants in HbA1C, alternative methods (Fructosamine) estimation is recommended for Glycemic Control

A: HbF >25%

- B: Homozygous Hemoglobinopathy.
- (Hb Electrophoresis is recommended method for detection of Hemoglobinopathy)

Page 6 of 16

Dr.Manju Kumari M.B.B.S,M.D(Pathology) Consultant Pathologist.

Dr.Tanish Mandal M.B.B.S,M.D(Pathology) Consultant Pathologist

SIN No:EDT240036851







Age/Gender : 39 Y 10 M 22 D/F

UHID/MR No : SCHI.0000019256

Visit ID : SCHIOPV28013

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : gtgrd Collected : 23/Mar/2024 10:36AM

Received : 23/Mar/2024 11:28AM Reported : 23/Mar/2024 10:46PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method		
LIPID PROFILE, SERUM						
TOTAL CHOLESTEROL	227	mg/dL	<200	CHE/CHO/POD		
TRIGLYCERIDES	95	mg/dL	<150	Enzymatic		
HDL CHOLESTEROL	52	mg/dL	>40	CHE/CHO/POD		
NON-HDL CHOLESTEROL	175	mg/dL	<130	Calculated		
LDL CHOLESTEROL	156	mg/dL	<100	Calculated		
VLDL CHOLESTEROL	19	mg/dL	<30	Calculated		
CHOL / HDL RATIO	4.37		0-4.97	Calculated		
ATHEROGENIC INDEX (AIP)	0.10		<0.11	Calculated		

Comment:

Reference Interval as per National Cholesterol Education Program (NCEP) Adult Treatment Panel III Report.

	Desirable	Borderline High	High	Very High
TOTAL CHOLESTEROL	< 200	200 - 239	≥ 240	
TRIGLYCERIDES	<150	150 - 199	200 - 499	≥ 500
LDL	Optimal < 100; Near Optimal 100- 129	130 - 159	160 - 189	≥ 190
HDL	≥ 60			
NON-HDL CHOLESTEROL	Optimal <130; Above Optimal 130-159	160-189	190-219	>220
ATHEROGENIC INDEX(AIP)	<0.11	0.12 - 0.20	>0.21	

Note:

- 1) Measurements in the same patient on different days can show physiological and analytical variations.
- 2) NCEP ATP III identifies non-HDL cholesterol as a secondary target of therapy in persons with high triglycerides.
- 3) Primary prevention algorithm now includes absolute risk estimation and lower LDL Cholesterol target levels to determine eligibility of drug therapy.

Page 7 of 16







Age/Gender : 39 Y 10 M 22 D/F UHID/MR No : SCHI.0000019256

Visit ID : SCHIOPV28013

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : gtgrd Collected : 23/Mar/2024 10:36AM

Received : 23/Mar/2024 11:28AM Reported : 23/Mar/2024 10:46PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - TMT - PAN INDIA - FY2324

- 4) Low HDL levels are associated with coronary heart disease due to insufficient HDL being available to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues.
- 5) As per NCEP guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.
- 6) VLDL, LDL Cholesterol Non-HDL Cholesterol, CHOL/HDL RATIO, LDL/HDL RATIO are calculated parameters when Triglycerides are below 400 mg/dl. When

Triglycerides are more than 400 mg/dl LDL cholesterol is a direct measurement.

7) Triglycerides and HDL-cholesterol in Atherogenic index (AIP) reflect the balance between the atherogenic and protective lipoproteins. Clinical studies have shown that AIP (log (TG/HDL) & values used are in mmol/L) predicts cardiovascular risk and a useful measure of response to treatment (pharmacological intervention).

Page 8 of 16







Age/Gender : 39 Y 10 M 22 D/F

UHID/MR No : SCHI.0000019256

Visit ID : SCHIOPV28013

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : gtgrd Collected : 23/Mar/2024 10:36AM

Received : 23/Mar/2024 11:28AM Reported : 23/Mar/2024 08:56PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
IVER FUNCTION TEST (LFT), SERUM				
BILIRUBIN, TOTAL	1.00	mg/dL	0.20-1.20	DIAZO METHOD
BILIRUBIN CONJUGATED (DIRECT)	0.40	mg/dL	0.0-0.3	Calculated
BILIRUBIN (INDIRECT)	0.60	mg/dL	0.0-1.1	Dual Wavelength
ALANINE AMINOTRANSFERASE (ALT/SGPT)	33	U/L	<35	Visible with P-5-P
ASPARTATE AMINOTRANSFERASE (AST/SGOT)	36.0	U/L	14-36	UV with P-5-P
ALKALINE PHOSPHATASE	89.00	U/L	38-126	p-nitrophenyl phosphate
PROTEIN, TOTAL	7.40	g/dL	6.3-8.2	Biuret
ALBUMIN	3.90	g/dL	3.5 - 5	Bromocresol Green
GLOBULIN	3.50	g/dL	2.0-3.5	Calculated
A/G RATIO	1.11		0.9-2.0	Calculated

Comment:

LFT results reflect different aspects of the health of the liver, i.e., hepatocyte integrity (AST & ALT), synthesis and secretion of bile (Bilirubin, ALP), cholestasis (ALP, GGT), protein synthesis (Albumin)

Common patterns seen:

1. Hepatocellular Injury:

- AST Elevated levels can be seen. However, it is not specific to liver and can be raised in cardiac and skeletal injuries.
- ALT Elevated levels indicate hepatocellular damage. It is considered to be most specific lab test for hepatocellular injury. Values also correlate well with increasing BMI. Disproportionate increase in AST, ALT compared with ALP. Bilirubin may be elevated.
- AST: ALT (ratio) In case of hepatocellular injury AST: ALT > 1In Alcoholic Liver Disease AST: ALT usually >2. This ratio is also seen to be increased in NAFLD, Wilsons's diseases, Cirrhosis, but the increase is usually not >2.

2. Cholestatic Pattern:

- ALP Disproportionate increase in ALP compared with AST, ALT.
- Bilirubin may be elevated.• ALP elevation also seen in pregnancy, impacted by age and sex.
- To establish the hepatic origin correlation with GGT helps. If GGT elevated indicates hepatic cause of increased ALP.
- 3. Synthetic function impairment: Albumin- Liver disease reduces albumin levels. Correlation with PT (Prothrombin Time) helps.

Page 9 of 16







Age/Gender : 39 Y 10 M 22 D/F UHID/MR No : SCHI.0000019256

UHID/MR No : SCHI.0000019256 Visit ID : SCHIOPV28013

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : gtgrd Collected : 23/Mar/2024 10:36AM
Received : 23/Mar/2024 11:28AM
Reported : 23/Mar/2024 08:56PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
RENAL PROFILE/KIDNEY FUNCTION	TEST (RFT/KFT), SER	RUM		
CREATININE	0.70	mg/dL	0.5-1.04	Creatinine amidohydrolase
UREA	25.60	mg/dL	15-36	Urease
BLOOD UREA NITROGEN	12.0	mg/dL	8.0 - 23.0	Calculated
URIC ACID	5.30	mg/dL	2.5-6.2	Uricase
CALCIUM	9.80	mg/dL	8.4 - 10.2	Arsenazo-III
PHOSPHORUS, INORGANIC	3.50	mg/dL	2.5-4.5	PMA Phenol
SODIUM	143	mmol/L	135-145	Direct ISE
POTASSIUM	4.8	mmol/L	3.5-5.1	Direct ISE
CHLORIDE	101	mmol/L	98 - 107	Direct ISE
PROTEIN, TOTAL	7.40	g/dL	6.3-8.2	Biuret
ALBUMIN	3.90	g/dL	3.5 - 5	Bromocresol Green
GLOBULIN	3.50	g/dL	2.0-3.5	Calculated
A/G RATIO	1.11		0.9-2.0	Calculated

Page 10 of 16







Age/Gender : 39 Y 10 M 22 D/F UHID/MR No : SCHI.0000019256

Visit ID : SCHIOPV28013

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : gtgrd Collected : 23/Mar/2024 10:36AM

Received : 23/Mar/2024 11:28AM Reported : 23/Mar/2024 07:14PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
GAMMA GLUTAMYL TRANSPEPTIDASE (GGT) , SERUM	18.00	U/L	12-43	Glyclyclycine Nitoranalide

Page 11 of 16









Age/Gender : 39 Y 10 M 22 D/F

UHID/MR No : SCHI.0000019256

Visit ID : SCHIOPV28013

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : gtgrd Collected : 23/Mar/2024 10:36AM

Received : 23/Mar/2024 05:01PM Reported : 23/Mar/2024 07:07PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF IMMUNOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
THYROID PROFILE TOTAL (T3, T4, TS)	H), SERUM			
TRI-IODOTHYRONINE (T3, TOTAL)	0.9	ng/mL	0.7-2.04	CLIA
THYROXINE (T4, TOTAL)	15.38	μg/dL	5.48-14.28	CLIA
THYROID STIMULATING HORMONE (TSH)	3.160	μIU/mL	0.34-5.60	CLIA

Kindly correlate clinically

Comment:

For pregnant females	Bio Ref Range for TSH in uIU/ml (As per American Thyroid Association)
First trimester	0.1 - 2.5
Second trimester	0.2 - 3.0
Third trimester	0.3 - 3.0

- 1. TSH is a glycoprotein hormone secreted by the anterior pituitary. TSH activates production of T3 (Triiodothyronine) and its prohormone T4 (Thyroxine). Increased blood level of T3 and T4 inhibit production of TSH.
- 2. TSH is elevated in primary hypothyroidism and will be low in primary hyperthyroidism. Elevated or low TSH in the context of normal free thyroxine is often referred to as sub-clinical hypo- or hyperthyroidism respectively.
- 3. Both T4 & T3 provides limited clinical information as both are highly bound to proteins in circulation and reflects mostly inactive hormone. Only a very small fraction of circulating hormone is free and biologically active.

4. Significant variations in TSH can occur with circadian rhythm, hormonal status, stress, sleep deprivation, medication & circulating antibodies.

TSH	Т3	T4	FT4	Conditions	
High	Low	Low	Low	Primary Hypothyroidism, Post Thyroidectomy, Chronic Autoimmune Thyroiditis	
High	N	N	N	Subclinical Hypothyroidism, Autoimmune Thyroiditis, Insufficient Hormone Replacement Therapy.	
N/Low	Low	Low	Low	Secondary and Tertiary Hypothyroidism	
Low	High	High	High	rimary Hyperthyroidism, Goitre, Thyroiditis, Drug effects, Early Pregnancy	
Low	N	N	N	ubclinical Hyperthyroidism	
Low	Low	Low	Low	entral Hypothyroidism, Treatment with Hyperthyroidism	
Low	N	High	High	hyroiditis, Interfering Antibodies	
N/Low	High	N	N	Thyrotoxicosis, Non thyroidal causes	
High	High	High	High	Pituitary Adenoma; TSHoma/Thyrotropinoma	

Page 12 of 16

Dr.Manju Kumari M.B.B.S,M.D(Pathology) Consultant Pathologist.

Dr.Tanish Mandal M.B.B.S,M.D(Pathology) Consultant Pathologist

SIN No:SPL24053874









: Mrs.POOJA KAPOOR

Age/Gender

: 39 Y 10 M 22 D/F

UHID/MR No

: SCHI.0000019256

Visit ID Ref Doctor : SCHIOPV28013

Emp/Auth/TPA ID

: Dr.SELF : gtgrd Collected

: 23/Mar/2024 10:36AM

Received

: 23/Mar/2024 05:01PM

Reported

: 23/Mar/2024 07:07PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF IMMUNOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - TMT - PAN INDIA - FY2324

Dr.Manju Kumari M.B.B.S,M.D(Pathology) Consultant Pathologist.

Dr.Tanish Mandal M.B.B.S,M.D(Pathology) Consultant Pathologist

SIN No:SPL24053874

Page 13 of 16





: Mrs.POOJA KAPOOR

Age/Gender

: 39 Y 10 M 22 D/F

UHID/MR No Visit ID : SCHI.0000019256

Ref Doctor

: SCHIOPV28013

Emp/Auth/TPA ID

: Dr.SELF : gtgrd Collected

: 23/Mar/2024 10:36AM

Received Reported : 23/Mar/2024 04:31PM : 23/Mar/2024 06:14PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED


DEPARTMENT OF CLINICAL PATHOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
COMPLETE URINE EXAMINATION (CUE) , URINE		<u>'</u>	<u>'</u>
PHYSICAL EXAMINATION				
COLOUR	PALE YELLOW		PALE YELLOW	Visual
TRANSPARENCY	CLEAR		CLEAR	Visual
рН	6.5		5-7.5	Bromothymol Blue
SP. GRAVITY	1.020		1.002-1.030	Dipstick
BIOCHEMICAL EXAMINATION				
URINE PROTEIN	NEGATIVE		NEGATIVE	PROTEIN ERROR OF INDICATOR
GLUCOSE	NEGATIVE		NEGATIVE	GOD-POD
URINE BILIRUBIN	NEGATIVE		NEGATIVE	AZO COUPLING
URINE KETONES (RANDOM)	NEGATIVE		NEGATIVE	NITROPRUSSIDE
UROBILINOGEN	NORMAL		NORMAL	EHRLICH
NITRITE	NEGATIVE		NEGATIVE	Dipstick
LEUCOCYTE ESTERASE	NEGATIVE		NEGATIVE	PYRROLE HYDROLYSIS
CENTRIFUGED SEDIMENT WET M	OUNT AND MICROSCOPY	1		
PUS CELLS	1-2	/hpf	0-5	Microscopy
EPITHELIAL CELLS	2-3	/hpf	<10	MICROSCOPY
RBC	ABSENT	/hpf	0-2	MICROSCOPY
CASTS	ABSENT		0-2 Hyaline Cast	MICROSCOPY
CRYSTALS	ABSENT		ABSENT	MICROSCOPY

Page 14 of 16







Visit ID



Patient Name : Mrs.POOJA KAPOOR

Age/Gender : 39 Y 10 M 22 D/F

UHID/MR No : SCHI.0000019256

: SCHIOPV28013

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : gtgrd Collected : 23/Mar/2024 10:36AM

Received : 23/Mar/2024 04:31PM Reported : 23/Mar/2024 06:14PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF CLINICAL PATHOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
URINE GLUCOSE(POST PRANDIAL)	NEGATIVE		NEGATIVE	Dipstick
Test Name	Result	Unit	Bio. Ref. Range	Method
URINE GLUCOSE(FASTING)	NEGATIVE		NEGATIVE	Dipstick

Dr. SHWETA GUPTA MBBS,MD (Pathology) Consultant Pathology

SIN No:UF011376



Page 15 of 16







: Mrs.POOJA KAPOOR

Age/Gender

: 39 Y 10 M 25 D/F

UHID/MR No

: SCHI.0000019256

Visit ID Ref Doctor : SCHIOPV28013

Emp/Auth/TPA ID

: Dr.SELF : gtgrd

Collected

: 26/Mar/2024 01:24PM

Received

: 26/Mar/2024 03:51PM

Reported

Status

: 28/Mar/2024 10:57AM

: Final Report

Sponsor Name


: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF CYTOLOGY

LBC PA	LBC PAP TEST (PAPSURE) , CERVICAL BRUSH SAMPLE			
	CYTOLOGY NO.	L/434/24		
I	SPECIMEN			
a	SPECIMEN ADEQUACY	ADEQUATE		
b	SPECIMEN TYPE	LIQUID-BASED PREPARATION (LBC)		
	SPECIMEN NATURE/SOURCE	CERVICAL SMEAR		
c	ENDOCERVICAL-TRANSFORMATION ZONE	PRESENT WITH ENDOCERVICAL CELLS		
d	COMMENTS	SATISFACTORY FOR EVALUATION		
П	MICROSCOPY	Smear shows sheets of superficial, intermediate squamous cells, along with clusters of endocervical cells.		
Ш	RESULT			
a	EPITHEIAL CELL			
	SQUAMOUS CELL ABNORMALITIES	NOT SEEN		
	GLANDULAR CELL ABNORMALITIES	NOT SEEN		
b	ORGANISM	NIL		
С	NON NEOPLASTIC FINDINGS	TUBAL METAPLASIA		
d	OTHERS	REACTIVE CHANGES SEEN		
IV	INTERPRETATION	NEGATIVE FOR INTRAEPITHELIAL LESION OR MALIGNANCY		

Pap Test is a screening test for cervical cancer with inherent false negative results. Regular screening and follow-up is recommended (Bethesda-TBS-2014) revised

*** End Of Report ***



SIN No:CS077733



Page 16 of 16



Consulction Pending

Doni

UHID:SCHI.0000019256 : Mrs. Pooja Kapoor Age: 39 Y Name Sex: F Address: eok baroda kunj g-54 OP Number: SCHIOPV28013 : ARCOFEMI MEDIWHEEL FEMALE AHC CREDIT PAN Bill No: SCHI-OCR-10068 Plan INDIA OP AGREEMENT Date : 23.03.2024 10:19 Department Serive Type/ServiceName Sno ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - TMT - PAN INDIA - FY2324 I GAMMA GLUTAMYL TRANFERASE (GGT) 2 LIVER FUNCTION TEST (LFT) 3 GLUCOSE, FASTING 4 HEMOGRAM + PERIPHERAL SMEAR 3 GYNAECOLOGY CONSULTATION 6 DIET CONSULTATION 7 COMPLETE URINE EXAMINATION 8 URINE GLUCOSE(POST PRANDIAL) 9 PERIPHERAL SMEAR TOECG 11 LBC PAP TEST- PAPSURE 12 RENAL PROFILE/RENAL FUNCTION TEST (RFT/KFT) 13 DENTAL CONSULTATION 14 GLUCOSE, POST PRANDIAL (PP), 2 HOURS (POST MEAL) 15 URINE GLUCOSE(FASTING) (To SONO MAMOGRAPHY - SCREENING 17 HbA1c, GLYCATED HEMOGLOBIN (18)X-RAY CHEST PA 19 ENT CONSULTATION 20 CARDIAC STRESS TEST(TMT) 21 FITNESS BY GENERAL PHYSICIAN 22 BLOOD GROUP ABO AND RH FACTOR 23 LIPID PROFILE 24 BODY MASS INDEX (BMI) (25) OPTHAL BY GENERAL PHYSICIAN 26 ULTRASOUND - WHOLE ABDOMEN V 27 THYROID PROFILE (TOTAL T3, TOTAL T4, TSH)

Height: 69 1 C3

Weight: 69 1 C3

B.P: 109 28

Pulse: 70



भारत सरकार GOVERNMENT OF INDIA



Pooja Kapoor जन्म तिथि / DOB : 01/05/1984 महिला / FEMALE Mobile No. 8587081726



4860 8478 2271

मेरा आधार, मेरी पहचान



भारतीय विशिष्ट पहचान प्राधिकरण UNIQUE IDENTIFICATION AUTHORITY OF INDIA

पता: W/O: रविंदर कपूर, म.न. 45 सी, मोती नगर, फोकल पोयंट एस.ओ, लुधियाना, पंजाब - 141010



Address W/O: Ravinder Kapoor H.N. 45 C Moti Nagar Focal Point S.O Ludhiana Punjab -

141010 **4860 8478 2271**









P.O. Box No. 1947 Bengaluru-560 00



To,

The Coordinator, Mediwheel (Arcofemi Healthcare Limited) Helpline number: 011- 41195959

Dear Sir / Madam,

Sub: Annual Health Checkup for the employees of Bank of Baroda

This is to inform you that the following spouse of our employee wishes to avail the facility of Cashless Annual Health Checkup provided by you in terms of our agreement.

PARTICULARS	OF HEALTH CHECK UP BENEFICIARY
NAME	POOJA KAPOOR
DATE OF BIRTH	01-05-1984
PROPOSED DATE OF HEALTH CHECKUP FOR EMPLOYEE SPOUSE	23-03-2024
BOOKING REFERENCE NO.	23M159424100102260S
	SPOUSE DETAILS
EMPLOYEE NAME	MR. KAPOOR RAVINDER
EMPLOYEE EC NO.	159424
EMPLOYEE DESIGNATION	BRANCH HEAD
EMPLOYEE PLACE OF WORK	NEW DELHI,NEHRU PLACE
EMPLOYEE BIRTHDATE	14-06-1982

This letter of approval / recommendation is valid if submitted along with copy of the Bank of Baroda employee id card. This approval is valid from 19-03-2024 till 31-03-2024. The list of medical tests to be conducted is provided in the annexure to this letter. Please note that the said health checkup is a cashless facility as per our tie up arrangement. We request you to attend to the health checkup requirement of our employee's spouse and accord your top priority and best resources in this regard. The EC Number and the booking reference number as given in the above table shall be mentioned in the invoice, invariably.

We solicit your co-operation in this regard.

Yours faithfully,

Sd/-

Chief General Manager HRM Department Bank of Baroda

(Note: This is a computer generated letter. No Signature required. For any clarification, please contact Mediwheel (Arcofemi Healthcare Limited))



Consulletion Reproly

CERTIFICATE OF MEDICAL FITNESS

This is	to certify that I have conducted the clinical examination	
of	Roofs barloon on 23/3	
Afteri	eviewing the medical history and on clinical examination it has been found /she is	
	OF THE PROPERTY OF THE STATE OF	Tick
ø.	Medically Fit	
D.	Fit with restrictions/recommendations	
3.7	Though following restrictions have been revealed, in my opinion, these are not impediments to the job.	
	1	
	<u></u>	
	3	
	However the employee should follow the advice/medication that has been communicated to him/her.	
	Review after	
	Currently Unfit.	
	Review after recommended	
18.	Unfit Unfit	A Phone is a distribution of the same and
	U (NEW COLHI) €	

Medical Officer
The Apollo Clinic, Uppal

This certificate is not meant for medico-legal purposes

PREVENTIVE HEALTH CARE SUMMARY

		THE BUN	IMARY
ola ba	1000	JHID No :	1900
- Jan Na	100/		1925
	712		
ofemi	U	XAMINEI	ON:- 23/
d .	Efclos H	ypolly	wdn on t
		1	Nil
		r :	Nil
	Other		Nil
· Nii			
			Active
	Allergi	ies :	Nil
Examination:			
cme.		2.1.	
: Kos	Pulse	10/ 12	bpm
	BP	105/-	CmmHg
was within norma	al limits.	11	18
ion:			
	is: Nil Nil Nil Nil Xamination: Kgs was within norma	Samination: Nil	RECEIPT N EXAMINE STATE EXAMINE EXAMINE Activity Nil Activity Nil Activity Allergies Kgs BP Normal Normal Normal Normal Normal Normal Normal Normal

PREVENTIVE HEALTH CARE SUMMARY

NAME:-	UHID No:	CURSON WASA
AGE:- SEX:	RECEIPT No : -	
PANEL:	EXAMINED ON:-	-

Investigations:

All the reports of tests and investigations are attached herewith

T chokeful 227

Recommendation:

Low fatdeel
Cep Absolute women 10 a p 1-2
My vike D3 60 konce a week
2-3 moth

Dr. Navneet Kaur Consultant Physician





Apollo Clinic

CONSENT FORM

Patient Name: Posta Kefovol Age: 39
UHID Number:
I Mr/Mrs/Ms PNJ Kofool Employee of (Company) Want to inform you that I am not interested in getting ANT PAP
(Company) Want to inform you that I am not interested in getting
Tests done which is a part of my routine health check package.
And I claim the above statement in my full consciousness.
Patient Signature: August Cabool Date: 26 03 2024



NAME:	POOJA	AGE/SEX:		YRS./F
UHID	19256			
REF BY:	APOLLO SPECTRA	DATE:-	23.03.	2024

ULTRASOUND WHOLE ABDOMEN

Liver: Appears normal in size and shows increased parenchymal echogenicity which is most likely due to fatty changes. Intrahepatic biliary radicles are not dilated. CBD and portal vein are normal in calibre.

Gall Bladder: normally distended with clear lumen and normal wall thickness. No calculus or sludge is seen.

Pancreas and Spleen: Appears normal in size and echotexture.

Both Kidneys: are normal in size, shape, and echopattern. The parenchymal thickness is normal and cortico-medullary differentiation is well maintained. Pelvicalyceal systems are not dilated. No calculus or mass lesion is seen. Ureter is not dilated.

Urinary Bladder: is moderately distended and shows no obvious calculus or sediments. Bladder wall thickness is normal.

Uterus is antiverted and normal in size. It measures 7.2x3.5cm. Outline is smooth. Myometrium is normal. Endometrial echoes are normal and measures 6.1 mm

Both ovaries are normal in size, shape and echotexture.

Right ovary: 2.8x1.6 cm Left ovary: 2.4x1.6 cm

No obvious adenexal mass is seen. No free fluid seen..


IMPRESSION: FATTY CHANGES IN LIVER GRADE 1

Please correlate clinically and with lab. Investigations.

DR. MONICA CHHABRACONSULTANT RADIOLOGIST

Dr. MONICA CHHABRA
Consultant Radiologist
DMC No. 18744
Apollo Spectra Hospitals
New Delhi-110019

Apollo Spectra Hospitals: Plot No. A-2, Chirag Enclave, Greater Kailash -1, New Delhi -110048 Ph: 011-40465555, 9910995018 | www.apollospectra.com



LMP-20/3/24

Bycle.

Period Ised.

Pal-NND

LCB-184V



Pooj a 404/F 26/3/24 Adv

Poreant, PIA PIS PIN (2) - Kactaryd Nou h

ance;

Apollo Spectra Hospitals: Plot No. A-2, Chirag Enclave, Greater Kailash -1, New Delhi -110048 Ph: 011-40465555, 9910995018 | www.apollospectra.com





Patient Name : Mrs.POOJA KAPOOR Age/Gender : 39 Y 10 M 22 D/F

UHID/MR No : SCHI.0000019256

Visit ID : SCHIOPV28013

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : gtgrd Collected : 23/Mar/2024 10:36AM Received : 23/Mar/2024 11:28AM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

: 23/Mar/2024 03:26PM

DEPARTMENT OF HAEMATOLOGY

Reported

PERIPHERAL SMEAR, WHOLE BLOOD EDTA

Dr. SHWETA GUPTA
MBBS,MD (Pathology)
Consultant Pathology
SIN No:BED240080214



Page 1 of 15





: Mrs.POOJA KAPOOR

Age/Gender

: 39 Y 10 M 22 D/F

UHID/MR No Visit ID

: SCHI.0000019256

Ref Doctor

: SCHIOPV28013

Emp/Auth/TPA ID

: Dr.SELF : gtgrd Collected

: 23/Mar/2024 10:36AM

Received

: 23/Mar/2024 11:28AM

Reported

: 23/Mar/2024 03:26PM

Status Sponsor Name : Final Report : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
HEMOGRAM , WHOLE BLOOD EDTA				
HAEMOGLOBIN	13.3	g/dL	12-15	CYANIDE FREE COLOUROMETER
PCV	41.40	%	40-50	PULSE HEIGHT AVERAGE
RBC COUNT	5.1	Million/cu.mm	3.8-4.8	Electrical Impedence
MCV	81.2	fL	83-101	Calculated
MCH	26.1	pg	27-32	Calculated
MCHC	32.1	g/dL	31.5-34.5	Calculated
R.D.W	15	%	11.6-14	Calculated
TOTAL LEUCOCYTE COUNT (TLC)	5,930	cells/cu.mm	4000-10000	Electrical Impedance
DIFFERENTIAL LEUCOCYTIC COUNT	(DLC)	'		<u>'</u>
NEUTROPHILS	55.2	%	40-80	Electrical Impedance
LYMPHOCYTES	32.3	%	20-40	Electrical Impedance
EOSINOPHILS	3.2	%	1-6	Electrical Impedance
MONOCYTES	8.5	%	2-10	Electrical Impedance
BASOPHILS	0.8	%	<1-2	Electrical Impedance
ABSOLUTE LEUCOCYTE COUNT		'		<u>'</u>
NEUTROPHILS	3273.36	Cells/cu.mm	2000-7000	Calculated
LYMPHOCYTES	1915.39	Cells/cu.mm	1000-3000	Calculated
EOSINOPHILS	189.76	Cells/cu.mm	20-500	Calculated
MONOCYTES	504.05	Cells/cu.mm	200-1000	Calculated
BASOPHILS	47.44	Cells/cu.mm	0-100	Calculated
Neutrophil lymphocyte ratio (NLR)	1.71		0.78- 3.53	Calculated
PLATELET COUNT	187000	cells/cu.mm	150000-410000	IMPEDENCE/MICROSCOPY
ERYTHROCYTE SEDIMENTATION RATE (ESR)	17	mm at the end of 1 hour	0-20	Modified Westergren
PERIPHERAL SMEAR				

RBCs ARE NORMOCYTIC NORMOCHROMIC.

TLC , DLC WITHIN NORMAL LIMIT. NO IMMATURE CELLS ARE SEEN. PLATELETS ARE ADEQUATE.

Page 2 of 15







Patient Name : Mrs.

: Mrs.POOJA KAPOOR

Age/Gender UHID/MR No : 39 Y 10 M 22 D/F : SCHI.0000019256

Visit ID

: SCHIOPV28013

Ref Doctor Emp/Auth/TPA ID : Dr.SELF : gtgrd Collected

: 23/Mar/2024 10:36AM : 23/Mar/2024 11:28AM

Received Reported

: 23/Mar/2024 11:26AW : 23/Mar/2024 03:26PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - TMT - PAN INDIA - FY2324

NO HEMOPARASITES SEEN

Page 3 of 15







Patient Name : Mrs.POOJA KAPOOR Age/Gender : 39 Y 10 M 22 D/F

UHID/MR No : SCHI.0000019256

Visit ID : SCHIOPV28013

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : gtgrd Collected : 23/Mar/2024 10:36AM Received : 23/Mar/2024 11:28AM

Reported : 23/Mar/2024 03:26PM Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED


DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
BLOOD GROUP ABO AND RH FACTOR	R, WHOLE BLOOD EDTA	4	<u>'</u>	
BLOOD GROUP TYPE	А			Forward & Reverse Grouping with Slide/Tube Aggluti
Rh TYPE	POSITIVE			Forward & Reverse Grouping with Slide/Tube Agglutination

Page 4 of 15









: Mrs.POOJA KAPOOR

Age/Gender

: 39 Y 10 M 22 D/F

UHID/MR No Visit ID : SCHI.0000019256 : SCHIOPV28013

Ref Doctor

: Dr.SELF

Emp/Auth/TPA ID : gtgrd

Collected

: 23/Mar/2024 03:44PM

Received

: 23/Mar/2024 04:11PM

Reported

Status

: 23/Mar/2024 08:59PM

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
GLUCOSE, FASTING, NAF PLASMA	95	mg/dL	70-100	GOD - POD

Comment:

As per American Diabetes Guidelines, 2023

Fasting Glucose Values in mg/dL	Interpretation
70-100 mg/dL	Normal
100-125 mg/dL	Prediabetes
≥126 mg/dL	Diabetes
<70 mg/dL	Hypoglycemia

Note:

- 1. The diagnosis of Diabetes requires a fasting plasma glucose of > or = 126 mg/dL and/or a random / 2 hr post glucose value of > or = 200 mg/dL on at least 2 occasions.
- 2. Very high glucose levels (>450 mg/dL in adults) may result in Diabetic Ketoacidosis & is considered critical.

Test Name	Result	Unit	Bio. Ref. Range	Method
GLUCOSE, POST PRANDIAL (PP), 2 HOURS, SODIUM FLUORIDE PLASMA (2 HR)	100	mg/dL	70-140	GOD - POD

Comment:

It is recommended that FBS and PPBS should be interpreted with respect to their Biological reference ranges and not with each other.

Conditions which may lead to lower postprandial glucose levels as compared to fasting glucose levels may be due to reactive hypoglycemia, dietary meal content, duration or timing of sampling after food digestion and absorption, medications such as insulin preparations, sulfonylureas, amylin analogues, or conditions such as overproduction of insulin.

Page 5 of 15







Patient Name : Mrs.POOJA KAPOOR Age/Gender : 39 Y 10 M 22 D/F

UHID/MR No : SCHI.0000019256

UHID/MR No : SCHI.0000019256 Visit ID : SCHIOPV28013

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : gtgrd Collected : 23/Mar/2024 10:36AM Received : 23/Mar/2024 03:35PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

: 23/Mar/2024 07:05PM

DEPARTMENT OF BIOCHEMISTRY

Reported

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
HBA1C (GLYCATED HEMOGLOBIN),	WHOLE BLOOD EDTA			
HBA1C, GLYCATED HEMOGLOBIN	5.6	%		HPLC
ESTIMATED AVERAGE GLUCOSE (eAG)	114	mg/dL		Calculated

Comment:

Reference Range as per American Diabetes Association (ADA) 2023 Guidelines:

REFERENCE GROUP	HBA1C %
NON DIABETIC	<5.7
PREDIABETES	5.7 - 6.4
DIABETES	≥ 6.5
DIABETICS	
EXCELLENT CONTROL	6 – 7
FAIR TO GOOD CONTROL	7 – 8
UNSATISFACTORY CONTROL	8 - 10
POOR CONTROL	>10

Note: Dietary preparation or fasting is not required.

- 1. HbA1C is recommended by American Diabetes Association for Diagnosing Diabetes and monitoring Glycemic Control by American Diabetes Association guidelines 2023.
- 2. Trends in HbA1C values is a better indicator of Glycemic control than a single test.
- 3. Low HbA1C in Non-Diabetic patients are associated with Anemia (Iron Deficiency/Hemolytic), Liver Disorders, Chronic Kidney Disease. Clinical Correlation is advised in interpretation of low Values.
- 4. Falsely low HbA1c (below 4%) may be observed in patients with clinical conditions that shorten erythrocyte life span or decrease mean erythrocyte age. HbA1c may not accurately reflect glycemic control when clinical conditions that affect erythrocyte survival are present.
- 5. In cases of Interference of Hemoglobin variants in HbA1C, alternative methods (Fructosamine) estimation is recommended for Glycemic Control

A: HbF >25%

- B: Homozygous Hemoglobinopathy.
- (Hb Electrophoresis is recommended method for detection of Hemoglobinopathy)

Page 6 of 15

Dr.Manju Kumari M.B.B.S,M.D(Pathology) Consultant Pathologist.

Dr.Tanish Mandal M.B.B.S,M.D(Pathology) Consultant Pathologist

SIN No:EDT240036851







: Mrs.POOJA KAPOOR

Age/Gender

: 39 Y 10 M 22 D/F

UHID/MR No

: SCHI.0000019256

Visit ID Ref Doctor : SCHIOPV28013

Emp/Auth/TPA ID

: Dr.SELF : gtgrd Collected

: 23/Mar/2024 10:36AM

Received

: 23/Mar/2024 11:28AM

Reported

: 23/Mar/2024 10:46PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method		
L IPID PROFILE , SERUM						
TOTAL CHOLESTEROL	227	mg/dL	<200	CHE/CHO/POD		
TRIGLYCERIDES	95	mg/dL	<150	Enzymatic		
HDL CHOLESTEROL	52	mg/dL	>40	CHE/CHO/POD		
NON-HDL CHOLESTEROL	175	mg/dL	<130	Calculated		
LDL CHOLESTEROL	156	mg/dL	<100	Calculated		
VLDL CHOLESTEROL	19	mg/dL	<30	Calculated		
CHOL / HDL RATIO	4.37		0-4.97	Calculated		
ATHEROGENIC INDEX (AIP)	0.10		<0.11	Calculated		

Comment:

Reference Interval as per National Cholesterol Education Program (NCEP) Adult Treatment Panel III Report.

	Desirable	Borderline High	High	Very High	
TOTAL CHOLESTEROL	< 200	200 - 239	≥ 240		
TRIGLYCERIDES	<150	150 - 199	200 - 499	≥ 500	
LDL	Optimal < 100; Near Optimal 100- 129	130 - 159	160 - 189	≥ 190	
HDL	≥ 60				
NON-HDL CHOLESTEROL	Optimal <130; Above Optimal 130-159	160-189	190-219	>220	
ATHEROGENIC INDEX(AIP)	<0.11	0.12 - 0.20	>0.21		

Note:

- 1) Measurements in the same patient on different days can show physiological and analytical variations.
- 2) NCEP ATP III identifies non-HDL cholesterol as a secondary target of therapy in persons with high triglycerides.
- 3) Primary prevention algorithm now includes absolute risk estimation and lower LDL Cholesterol target levels to determine eligibility of drug therapy.

Page 7 of 15







Age/Gender : 39 Y 10 M 22 D/F UHID/MR No : SCHI.0000019256

Visit ID : SCHIOPV28013

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : gtgrd Collected : 23/Mar/2024 10:36AM

Received : 23/Mar/2024 11:28AM Reported : 23/Mar/2024 10:46PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - TMT - PAN INDIA - FY2324

- 4) Low HDL levels are associated with coronary heart disease due to insufficient HDL being available to participate in reverse cholesterol transport, the process by which cholesterol is eliminated from peripheral tissues.
- 5) As per NCEP guidelines, all adults above the age of 20 years should be screened for lipid status. Selective screening of children above the age of 2 years with a family history of premature cardiovascular disease or those with at least one parent with high total cholesterol is recommended.
- 6) VLDL, LDL Cholesterol Non-HDL Cholesterol, CHOL/HDL RATIO, LDL/HDL RATIO are calculated parameters when Triglycerides are below 400 mg/dl. When

Triglycerides are more than 400 mg/dl LDL cholesterol is a direct measurement.

7) Triglycerides and HDL-cholesterol in Atherogenic index (AIP) reflect the balance between the atherogenic and protective lipoproteins. Clinical studies have shown that AIP (log (TG/HDL) & values used are in mmol/L) predicts cardiovascular risk and a useful measure of response to treatment (pharmacological intervention).

Page 8 of 15







Age/Gender : 39 Y 10 M 22 D/F

UHID/MR No : SCHI.0000019256

Visit ID : SCHIOPV28013

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : gtgrd Collected : 23/Mar/2024 10:36AM Received : 23/Mar/2024 11:28AM

Reported : 23/Mar/2024 08:56PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
LIVER FUNCTION TEST (LFT), SERUM				
BILIRUBIN, TOTAL	1.00	mg/dL	0.20-1.20	DIAZO METHOD
BILIRUBIN CONJUGATED (DIRECT)	0.40	mg/dL	0.0-0.3	Calculated
BILIRUBIN (INDIRECT)	0.60	mg/dL	0.0-1.1	Dual Wavelength
ALANINE AMINOTRANSFERASE (ALT/SGPT)	33	U/L	<35	Visible with P-5-P
ASPARTATE AMINOTRANSFERASE (AST/SGOT)	36.0	U/L	14-36	UV with P-5-P
ALKALINE PHOSPHATASE	89.00	U/L	38-126	p-nitrophenyl phosphate
PROTEIN, TOTAL	7.40	g/dL	6.3-8.2	Biuret
ALBUMIN	3.90	g/dL	3.5 - 5	Bromocresol Green
GLOBULIN	3.50	g/dL	2.0-3.5	Calculated
A/G RATIO	1.11		0.9-2.0	Calculated

Comment:

LFT results reflect different aspects of the health of the liver, i.e., hepatocyte integrity (AST & ALT), synthesis and secretion of bile (Bilirubin, ALP), cholestasis (ALP, GGT), protein synthesis (Albumin)

Common patterns seen:

1. Hepatocellular Injury:

- AST Elevated levels can be seen. However, it is not specific to liver and can be raised in cardiac and skeletal injuries.
- ALT Elevated levels indicate hepatocellular damage. It is considered to be most specific lab test for hepatocellular injury. Values also correlate well with increasing BMI. Disproportionate increase in AST, ALT compared with ALP. Bilirubin may be elevated.
- AST: ALT (ratio) In case of hepatocellular injury AST: ALT > 1In Alcoholic Liver Disease AST: ALT usually >2. This ratio is also seen to be increased in NAFLD, Wilsons's diseases, Cirrhosis, but the increase is usually not >2.

2. Cholestatic Pattern:

- ALP Disproportionate increase in ALP compared with AST, ALT.
- Bilirubin may be elevated.• ALP elevation also seen in pregnancy, impacted by age and sex.
- To establish the hepatic origin correlation with GGT helps. If GGT elevated indicates hepatic cause of increased ALP.
- 3. Synthetic function impairment: Albumin- Liver disease reduces albumin levels. Correlation with PT (Prothrombin Time) helps.

Page 9 of 15







Age/Gender : 39 Y 10 M 22 D/F UHID/MR No : SCHI.0000019256

Visit ID : SCHIOPV28013

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : gtgrd Collected : 23/Mar/2024 10:36AM
Received : 23/Mar/2024 11:28AM
Reported : 23/Mar/2024 08:56PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
RENAL PROFILE/KIDNEY FUNCTION	TEST (RFT/KFT), SEF	RUM		
CREATININE	0.70	mg/dL	0.5-1.04	Creatinine amidohydrolase
UREA	25.60	mg/dL	15-36	Urease
BLOOD UREA NITROGEN	12.0	mg/dL	8.0 - 23.0	Calculated
URIC ACID	5.30	mg/dL	2.5-6.2	Uricase
CALCIUM	9.80	mg/dL	8.4 - 10.2	Arsenazo-III
PHOSPHORUS, INORGANIC	3.50	mg/dL	2.5-4.5	PMA Phenol
SODIUM	143	mmol/L	135-145	Direct ISE
POTASSIUM	4.8	mmol/L	3.5-5.1	Direct ISE
CHLORIDE	101	mmol/L	98 - 107	Direct ISE
PROTEIN, TOTAL	7.40	g/dL	6.3-8.2	Biuret
ALBUMIN	3.90	g/dL	3.5 - 5	Bromocresol Green
GLOBULIN	3.50	g/dL	2.0-3.5	Calculated
A/G RATIO	1.11		0.9-2.0	Calculated

Page 10 of 15







Patient Name : Mrs.POOJA KAPOOR Age/Gender : 39 Y 10 M 22 D/F

UHID/MR No : SCHI.0000019256

Visit ID : SCHIOPV28013

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : gtgrd Collected : 23/Mar/2024 10:36AM

Received : 23/Mar/2024 11:28AM Reported : 23/Mar/2024 07:14PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
GAMMA GLUTAMYL TRANSPEPTIDASE (GGT) , SERUM	18.00	U/L	12-43	Glyclyclycine Nitoranalide

Page 11 of 15







Age/Gender : 39 Y 10 M 22 D/F

UHID/MR No : SCHI.0000019256

Visit ID : SCHIOPV28013

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : gtgrd Collected : 23/Mar/2024 10:36AM

Received : 23/Mar/2024 05:01PM

Reported : 23/Mar/2024 07:07PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF IMMUNOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method	
THYROID PROFILE TOTAL (T3, T4, TSH), SERUM					
TRI-IODOTHYRONINE (T3, TOTAL)	0.9	ng/mL	0.7-2.04	CLIA	
THYROXINE (T4, TOTAL)	15.38	μg/dL	5.48-14.28	CLIA	
THYROID STIMULATING HORMONE (TSH)	3.160	μIU/mL	0.34-5.60	CLIA	

Kindly correlate clinically

Comment:

For pregnant females	Bio Ref Range for TSH in uIU/ml (As per American Thyroid Association)			
First trimester	0.1 - 2.5			
Second trimester	0.2 - 3.0			
Third trimester	0.3 - 3.0			

- 1. TSH is a glycoprotein hormone secreted by the anterior pituitary. TSH activates production of T3 (Triiodothyronine) and its prohormone T4 (Thyroxine). Increased blood level of T3 and T4 inhibit production of TSH.
- **2.** TSH is elevated in primary hypothyroidism and will be low in primary hyperthyroidism. Elevated or low TSH in the context of normal free thyroxine is often referred to as sub-clinical hypo- or hyperthyroidism respectively.
- 3. Both T4 & T3 provides limited clinical information as both are highly bound to proteins in circulation and reflects mostly inactive hormone. Only a very small fraction of circulating hormone is free and biologically active.


4. Significant variations in TSH can occur with circadian rhythm, hormonal status, stress, sleep deprivation, medication & circulating antibodies.

TSH	Т3	T4	FT4	Conditions
High	Low	Low	Low	Primary Hypothyroidism, Post Thyroidectomy, Chronic Autoimmune Thyroiditis
High	N	N	N	Subclinical Hypothyroidism, Autoimmune Thyroiditis, Insufficient Hormone Replacement Therapy.
N/Low	Low	Low	Low	Secondary and Tertiary Hypothyroidism
Low	High	High	High	Primary Hyperthyroidism, Goitre, Thyroiditis, Drug effects, Early Pregnancy
Low	N	N	N	Subclinical Hyperthyroidism
Low	Low	Low	Low	Central Hypothyroidism, Treatment with Hyperthyroidism
Low	N	High	High	Thyroiditis, Interfering Antibodies
N/Low	High	N	N	T3 Thyrotoxicosis, Non thyroidal causes
High	High	High	High	Pituitary Adenoma; TSHoma/Thyrotropinoma

Page 12 of 15

Dr.Manju Kumari M.B.B.S,M.D(Pathology) Consultant Pathologist.

SIN No:SPL24053874











: Mrs.POOJA KAPOOR

Age/Gender

: 39 Y 10 M 22 D/F

UHID/MR No

: SCHI.0000019256

Visit ID Ref Doctor : SCHIOPV28013

Emp/Auth/TPA ID

: Dr.SELF

: gtgrd

Collected

: 23/Mar/2024 10:36AM

Received

: 23/Mar/2024 05:01PM

Reported

: 23/Mar/2024 07:07PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF IMMUNOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - TMT - PAN INDIA - FY2324

Dr.Manju Kumari M.B.B.S, M.D (Pathology) Consultant Pathologist.

SIN No:SPL24053874

Dr. Tanish Mandal M.B.B.S,M.D(Pathology) Consultant Pathologist





Page 13 of 15





: Mrs.POOJA KAPOOR

Age/Gender

: 39 Y 10 M 22 D/F

UHID/MR No

: SCHI.0000019256

Visit ID Ref Doctor : SCHIOPV28013

Emp/Auth/TPA ID

: Dr.SELF : gtgrd

Collected

: 23/Mar/2024 10:36AM

Received

: 23/Mar/2024 04:31PM

Reported

Status

: 23/Mar/2024 06:14PM

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED


DEPARTMENT OF CLINICAL PATHOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Range	Method
COMPLETE URINE EXAMINATION (CUE) , URINE		<u>'</u>	
PHYSICAL EXAMINATION				
COLOUR	PALE YELLOW		PALE YELLOW	Visual
TRANSPARENCY	CLEAR		CLEAR	Visual
рН	6.5		5-7.5	Bromothymol Blue
SP. GRAVITY	1.020		1.002-1.030	Dipstick
BIOCHEMICAL EXAMINATION				
URINE PROTEIN	NEGATIVE		NEGATIVE	PROTEIN ERROR OF INDICATOR
GLUCOSE	NEGATIVE		NEGATIVE	GOD-POD
URINE BILIRUBIN	NEGATIVE		NEGATIVE	AZO COUPLING
URINE KETONES (RANDOM)	NEGATIVE		NEGATIVE	NITROPRUSSIDE
UROBILINOGEN	NORMAL		NORMAL	EHRLICH
NITRITE	NEGATIVE		NEGATIVE	Dipstick
LEUCOCYTE ESTERASE	NEGATIVE		NEGATIVE	PYRROLE HYDROLYSIS
CENTRIFUGED SEDIMENT WET M	OUNT AND MICROSCOPY	1		
PUS CELLS	1-2	/hpf	0-5	Microscopy
EPITHELIAL CELLS	2-3	/hpf	<10	MICROSCOPY
RBC	ABSENT	/hpf	0-2	MICROSCOPY
CASTS	ABSENT		0-2 Hyaline Cast	MICROSCOPY
CRYSTALS	ABSENT		ABSENT	MICROSCOPY

Page 14 of 15









Age/Gender : 39 Y 10 M 22 D/F

UHID/MR No : SCHI.0000019256

Visit ID : SCHIOPV28013
Ref Doctor : Dr.SELF

Emp/Auth/TPA ID : gtgrd

Collected : 23/Mar/2024 10:36AM

Received : 23/Mar/2024 04:31PM Reported : 23/Mar/2024 06:14PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF CLINICAL PATHOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS CHECK ADVANCED - FEMALE - TMT - PAN INDIA - FY2324

Test Name	Result	Unit Bio. Ref. Range		Method	
URINE GLUCOSE(POST PRANDIAL)	NEGATIVE		NEGATIVE	Dipstick	
Test Name	Result	Unit	Bio. Ref. Range	Method	
		• • • • • • • • • • • • • • • • • • • •	Dioi iton itango		

*** End Of Report ***

Page 15 of 15

